NDUFV2

NDUFV2 encodes the 24-kDa [2Fe-2S] iron–sulfur subunit (cluster N1a) of the NADH-dehydrogenase N-module of mitochondrial respiratory complex I, serving as an essential determinant of complex I assembly, activity, and supercomplex organization. Its N-terminal amphiphilic presequence directs mitochondrial import with cleavage around residue 32, and disruption of this targeting — as occurs with the IVS2+5_+8delGTAA splice-site mutation — abolishes import and causes complex I deficiency (PMID:21548921, PMID:12754703). Transcription is driven by Sp1 binding to GC-boxes in the TATA-less promoter (PMID:17786189); at the post-translational level, Src-mediated phosphorylation of Tyr118 inhibits complex I activity during ischemia–reperfusion (PMID:28219781), while physical interaction with PHB2 stabilizes NDUFV2 protein and sustains oxidative phosphorylation (PMID:37451140). Loss-of-function mutations cause complex I deficiency presenting as hypertrophic cardiomyopathy, Leigh-like encephalopathy, or progressive cavitating leukoencephalopathy (PMID:12754703, PMID:33811136).

1. 1995 High

   Establishing the molecular identity of NDUFV2 as the 24-kDa [2Fe-2S] complex I subunit mapped to 18p11 resolved which nuclear gene encodes this iron–sulfur center and revealed a TATA-less, GC-box-containing promoter architecture.

   Evidence Molecular cloning, FISH mapping, and genomic sequencing by two independent groups

   PMID:7488192 PMID:7607668

   Open questions at the time

   • No functional demonstration that the GC-boxes drive transcription
   • No disease mutations yet identified
   • Mitochondrial import mechanism not characterized
2. 2003 High

   Identification of the IVS2+5_+8delGTAA splice-site mutation causing 70% loss of NDUFV2 protein and complex I deficiency demonstrated that NDUFV2 loss-of-function is sufficient to cause early-onset hypertrophic cardiomyopathy and encephalopathy.

   Evidence DHPLC/sequencing of patient DNA with protein quantification in affected tissue

   PMID:12754703

   Open questions at the time

   • Pathomechanism (impaired import vs. protein instability) not yet distinguished
   • No complementation rescue performed
   • Only a single family studied
3. 2004 Medium

   A promoter polymorphism (−602G>A) was shown to alter NDUFV2 transcriptional activity and associate with bipolar disorder, providing the first evidence that quantitative variation in NDUFV2 expression has neuropsychiatric consequences.

   Evidence Luciferase promoter-reporter assay combined with case-control and TDT genetic association

   PMID:15450783

   Open questions at the time

   • Association not replicated across multiple independent cohorts at the time
   • Downstream effect on complex I activity in brain not measured
   • Causal transcription-factor binding change at −602 not identified
4. 2007 High

   Demonstrating that Sp1 directly binds the three GC-boxes and activates NDUFV2 transcription resolved the transcriptional regulation of this TATA-less gene.

   Evidence ChIP, promoter-reporter assays, and mithramycin inhibition in neuroblastoma cells

   PMID:17786189

   Open questions at the time

   • Additional transcription factors or chromatin regulators not explored
   • Tissue-specific regulation not addressed
   • Link between Sp1 activity changes and disease states not tested
5. 2011 High

   Mapping the mitochondrial targeting sequence to residues 1–22 and the cleavage site to ~residue 32 established that the IVS2-linked deletion (Δ19–40) causes disease specifically by abolishing mitochondrial import of NDUFV2.

   Evidence GFP/c-myc fusion constructs with site-directed mutagenesis and confocal microscopy

   PMID:21548921

   Open questions at the time

   • Import pathway components (TIM/TOM dependence) not identified
   • Whether partially imported mutant protein is degraded was not shown
   • Complementation in patient cells not performed
6. 2017 High

   Identification of Src-mediated Tyr118 phosphorylation as a negative regulatory switch for complex I activity revealed a rapid post-translational mechanism linking receptor signaling to mitochondrial electron transport during ischemia–reperfusion.

   Evidence LC-MS phosphoproteomics, Y118F mutagenesis, complex I activity assay, and rat heart ischemia–reperfusion model

   PMID:28219781

   Open questions at the time

   • Structural basis for how pY118 inhibits electron transfer through the N1a cluster not resolved
   • Whether other kinases phosphorylate NDUFV2 at additional sites is unknown
   • In vivo significance beyond cardiac ischemia–reperfusion not tested
7. 2018 Medium

   Discovery that the pseudogene NDUFV2P1 inversely regulates NDUFV2 protein level without affecting mRNA suggested a post-transcriptional layer of complex I regulation relevant to schizophrenia-associated bioenergetic deficits.

   Evidence qRT-PCR, Western blot, and Seahorse respirometry in patient-derived cell lines and postmortem brain

   PMID:30531937

   Open questions at the time

   • Mechanism of pseudogene-mediated post-transcriptional regulation not reconstituted
   • Causal role of NDUFV2P1 not demonstrated by knockdown/overexpression rescue
   • Findings limited to correlative patient-derived material
8. 2021 High

   In vivo overexpression of Ndufv2 in adipose tissue showed it promotes mitochondrial supercomplex assembly and ROS-driven retrograde signaling that increases mitochondrial biogenesis in a sex-specific manner, extending NDUFV2's role beyond electron transfer to organelle homeostasis.

   Evidence Mouse adipose-specific overexpression, BN-PAGE supercomplex assay, mitochondrial ROS measurement, transcriptomics across inbred strains

   PMID:34697471

   Open questions at the time

   • Whether the supercomplex-assembly function is direct or secondary to increased N-module incorporation is unclear
   • Mechanism of sex specificity not identified
   • Relevance to non-adipose tissues not established
9. 2021 High

   cDNA complementation rescue of complex I deficiency in fibroblasts from patients carrying novel NDUFV2 missense mutations confirmed causality for progressive cavitating leukoencephalopathy, broadening the phenotypic spectrum of NDUFV2-linked disease.

   Evidence Whole-exome sequencing plus cDNA complementation and complex I activity assay in patient fibroblasts

   PMID:33811136

   Open questions at the time

   • Structural effects of individual missense mutations on the [2Fe-2S] cluster not resolved
   • Genotype–phenotype correlation across cardiomyopathy vs. leukoencephalopathy not mechanistically explained
   • No animal model recapitulating these specific mutations
10. 2023 High

    Demonstrating that PHB2 physically interacts with and stabilizes NDUFV2 protein identified a chaperone-like quality-control mechanism for maintaining complex I integrity, particularly under cardiotoxic stress.

    Evidence Reciprocal Co-IP, pulldown, proteomics, cardiac-specific PHB2 knockout mice, doxorubicin cardiotoxicity model

    PMID:37451140

    Open questions at the time

    • Whether PHB2 stabilizes NDUFV2 during or after mitochondrial import is unknown
    • Binding interface between PHB2 and NDUFV2 not mapped
    • Whether PHB2 similarly stabilizes other N-module subunits not tested

• A high-resolution structural understanding of how post-translational modifications (Tyr118 phosphorylation) and protein–protein interactions (PHB2 binding) regulate NDUFV2 within the assembled complex I supercomplex, and how genotype dictates tissue-specific disease manifestation, remains unresolved.
• No atomic-resolution structure of human NDUFV2 in context of modified or PHB2-bound complex I
• Mechanism underlying tissue-specific and sex-specific phenotypic outcomes not elucidated
• Contribution of pseudogene NDUFV2P1 to complex I regulation awaits direct genetic perturbation